• 대한후두음성언어의학회지
• /
• 제28권2호
• /
• pp.123-127
• /
• 2017

Background and Objectives : Contact granuloma is granulation tissue that occurs mainly in the vocal process of arytenoid cartilage. Among several etiological factors, gastric acid reflux is known to be an important cause. The aim of this study was to evaluate clinical characteristics of contact granuloma and analyze the effectiveness of proton pump inhibitor in the treatment of contact granuloma. Materials and Methods : We retrospectively reviewed the medical records of 40 patients who were treated with proton pump inhibitor (PPI) for contact granuloma from January 2011 to December 2015. Reflux finding score (RFS), reflux symptom index (RSI) and size of granuloma were evaluated before and after treatment serially to assess the effectiveness of proton pump inhibitor. Results : Of 40 patients, 25 patients (62.5%) and 10 patients (25%) showed improvement and partial improvement of granuloma, respectively. Five patients showed no response. The mean times of partial improvement and improvement were $2.08{\pm}2.23$ months and $4.60{\pm}2.77$ months, respectively and mean duration of PPI treatment was $6.8{\pm}5.2$ months. Conclusion : Proton pump inhibitors is effective in the treatment of contact granuloma.

• 대한기관식도과학회지
• /
• 제16권2호
• /
• pp.97-104
• /
• 2010

Gastroesophageal reflux disease (GERD) is a common disorder caused by the reflux of gastric contents into the esophagus. According to the recent classification, GERD can elicit esophageal and extraesophageal syndromes. Laryngopharyngeal reflux (LPR) is defined as laryngeal symptoms with laryngeal inflammation caused by the acid reflux. The prevalence of GERD and LPR is increasing during the past decades in Korea and management of GERD and LPR is a challenging issue in clinical practice. Proton pump inhibitor is the most effective drug in the treatment of GERD. Most patients with LPR are given a 2-month trial of a proton pump inhibitor (PPI), however, there is still little evidence on the diagnosis or the treatment of LPR. During the last years concern have been raised regarding the risk of averse events related to long-term use of PPI. We review the recent update on medical treatment of GERD/LPR.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1997년도 춘계학술대회
• /
• pp.100-100
• /
• 1997

To treat peptic ulcer diseases, many potent proton pump inhibitors have been developed for suppressing the gastric acid secretion in clinical patients. However, most of these agents have common irreversible mechanisms against H$\^$+/, K$\^$+/-ATPase which might be the cause of hypergastrinemia and ECL cell hyperplasia. Therefore, the development of new reversible inhibitors is prompted. In this study, we investigated the inhibitory mechanism of a newly synthesized proton pump inhibitor, YJA20379-8 using lyophilized hog gastric microsomes. YJA20379-8 inhibited K$\^$+/-stimulated H$\^$+/K$\^$+/-ATPase activity uncompetitively with respect to K$\^$+/, and in the other hand, showed competitive inhibitory pattern with ATP, respectively. From these data, we suggest that YJA20379-8 may be a proton pump inhibitor with a new inhibitory mechanism.

• Tuberculosis and Respiratory Diseases
• /
• 제61권2호
• /
• pp.137-142
• /
• 2006

연구배경: 8주 이상 지속되는 만성 기침의 원인 중 하나인 위식도역류질환는 환자의 약 75%가 증상이 없으며, 진단을 위한 24시간 식도 pH감시가 침습적이고 검사가 어려워 진단 및 치료에 어려움이 있다. 따라서 만성 기침환자 중 후비루증후군 및 기관지 천식이 아닌 환자를 대상으로 양자펌프억제제를 투여하고 치료효과를 관찰하였다. 방법 및 대상: 기침증상이 8주 이상인 만성기침 환자 중 X-ray 소견상 이상이 없고 메타콜린 기관지유발시험상 음성이며, 후비루증후군 치료에 반응이 없었던 40명을 대상으로 하였다. 8주 이상 양자펌프억제제를 투여하였으며 50%이상 기침이 감소한 경우를 부분 반응군, 기침이 거의 소실된 경우를 완전 반응군으로 분류하였다. 결 과: 대상자 40명중 29명만이 4주 이상 추적되었으며 이중 26명만이 8주까지 추적 관찰되었다. 29명중 남자가 9명, 여자가 20명이었으며 평균나이는 51세였다. 대상자들에서 기침 이외의 증상은 객담이 12%, 콧물이나 비폐색 등의 코 증상이 있는 환자는 10%, 속쓰림, 소화불량 등의 소화기 증상을 호소하는 환자는 13.4%였다. 29명중 4주간 투여 후 증상의 호전이 없는 환자가 3명(10.3%), 50% 이상의 증상호전을 보이는 환자가 22명(75.9%), 그리고 증상이 거의 소실된 환자가 4명(13.8%)로 약 90%정도의 환자가 기침의 증상호전이 있었다. 8주 투여 후 호전이 없는 환자가 2명(7.4%), 50% 이상 증상호전이 있는 환자가 8명(29.6%), 증상이 거의 소실된 환자가 16명(63.0%)이었다. 결 론: 8주이상의 만성기침 환자에서 8주 이상 양자펌프억제제 투여 후 92.6%환자가 증상호전이 있었으며 이중 63%는 거의 소실되었다. 하지만 본 연구는 위약을 통한 대조군이 없는 관계로 그 결과의 해석에 어려움이 있다. 앞으로 좀더 많은 환자를 대상으로 하는 이중맹검시험이 필요할 것으로 생각된다.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2002년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
• /
• pp.223-224
• /
• 2002

Pharmacokinetic (PK) and pharmacodynamic (PD) study of a new reversible proton pump inhibitor (YH1885, Yuhan Pharmaceutical Co.) was done as a phase 1 clinical trial in Seoul national University Hospital Clinical trialcenter. Single dose of 60, 100, 150, 200, and 300mg were administered to total 20 healthy subjects under fasting state. Six subjects were given 100 mg after food and 12 subjects were given multiple doses of 150 and 300 mg every day for 7 days under fasting state. (omitted)

• Journal of Digestive Cancer Research
• /
• 제10권1호
• /
• pp.9-15
• /
• 2022

Proton pump inhibitors (PPIs), a potent gastric acid inhibitor, are widely used in gastric acid-related diseases such as gastroesophageal reflux disease and peptic ulcer, and are known as the most frequently used drugs worldwide. However, as the frequency of use increases, the number of cases of long-term PPI therapy without clear indications is increasing. Recently, there have been concerns about the risk of gastric cancer in patients with long-term PPI users. Potential mechanisms for the association between PPI and gastric cancer include enterochromaffin-like cell proliferation due to hypergastrinemia caused by gastric acid suppression, progression of atrophic gastritis, and corpus-predominant type through interaction with Helicobacter pylori (H. pylori) infection. Several epidemiologic studies showed controversial results on the issue, and it is difficult to prove a causal relationship between PPI and gastric cancer. Nevertheless, long-term PPI should be administered cautiously based on individual risk-benefit profile, specifically among those with history of H. pylori infection, in high-risk region of gastric cancer.

• Journal of Neurogastroenterology and Motility
• /
• 제24권4호
• /
• pp.577-583
• /
• 2018

Background/Aims Potassium-competitive acid blockers are expected to be the next generation of drugs for the treatment of diseases caused by gastric acid. In 2015, vonoprazan fumarate, a novel potassium-competitive acid blocker, was approved by the Japanese health insurance system. Since its approval, patients refractory to vonoprazan can be encountered in clinical settings. We designed this study to clarify the pathophysiology of gastroesophageal reflux disease refractory to vonoprazan. Methods In this retrospective study, we involved patients who had refractory symptoms after administration of standard-dose proton pump inhibitors or vonoprazan and underwent diagnostic testing with esophageal high-resolution manometry and 24-hour multichannel intraluminal impedance and pH monitoring while using proton pump inhibitors or vonoprazan. Patients were diagnosed based on the Rome IV criteria for functional gastrointestinal disorders and diagnostic test results. Results Twenty-seven patients were analyzed during this study. Gastric pH ${\geq}4$ was sustained for a longer period of time, and the esophageal acid exposure time and number of acid reflux events were shorter in the vonoprazan group than in the proton pump inhibitor group. The percentage of patients diagnosed with acidic gastroesophageal reflux disease in the vonoprazan group was lower than that in the proton pump inhibitor group. Conclusions Intra-gastric pH and acid reflux were strongly suppressed by 20-mg vonoprazan. When patients with gastroesophageal reflux disease present symptoms after administration of 20-mg vonoprazan, the possibility of pathophysiologies other than acid reflux should be considered.

• Clinical Endoscopy
• /
• 제57권1호
• /
• pp.51-52
• /
• 2024

• 약학회지
• /
• 제41권2호
• /
• pp.174-180
• /
• 1997

Four oxazolidinone analogues(6, 7, 8, 9), which are isosters of 5, were synthesized by the reaction of 2-chloroalkyl-3,5-dimethyl-4-methoxypyridine with the corresponding benzox azolidinone or oxazolidinone, respectively, and were evaluated for their inhibitory activities toward proton pump enzyme under in vitro condition. Isosteric substitution of the benzothiazolidine moiety in 5 with benzoxazolidinone rendered the molecule relatively inactive.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.1
• /
• pp.311.1-311.1
• /
• 2003

Dose-independent pharmacokinetic parameters of KR-60436, a new proton pump inhibitor, were evaluated after an intravenous, iv (5, 10, and 20 mg/kg) and an oral (20, 50, and 100 mg/kg) administration to rats. The hepatic, gastric, and intestinal first-pass effects were also measured after iv, intraportal (ip), intragastric (ig), and intraduodenal (id) administration at a dose of 20 mg/kg to rats. (omitted)